Switzerland Market Access: Navigating Reimbursement & Achieving Patient Access
Switzerland is a unique and highly attractive market for pharmaceutical innovation, known for its high-quality healthcare system and strong commitment to patient access. However, successfully launching and ensuring sustainable reimbursement for new therapies in Switzerland requires a deep understanding of its specific regulatory and health technology assessment (HTA) landscape.
At Sur Access, we specialize in Health Technology Assessment (HTA) in Switzerland, helping pharmaceutical and biotech companies effectively demonstrate the value of their innovative products to ensure optimal patient access. We combine our expertise in evidence synthesis, economic modeling, and strategic communication with an in-depth understanding of the Swiss healthcare system.
Our Collaborative Approach: Sur Access & Our Partners
Navigating the Swiss market entry requires a dual approach: robust regulatory approval and compelling HTA/reimbursement dossiers. We are proud to partner with leading experts in Swiss regulatory affairs and corporate services. This strategic collaboration ensures a seamless, integrated process from regulatory submission to successful reimbursement and compliant local establishment.
Sur Access' Focus: HTA & Value Demonstration
Developing and refining your product's value story specifically for the Swiss context.
Strategic guidance on evidence generation to meet Swiss HTA requirements for Effectiveness, Appropriateness, and Economic Efficiency (WZW criteria).
Preparation of comprehensive HTA dossiers, focusing on robust clinical and economic arguments for reimbursement.
Support for economic assessments required by the FOPH, including the development of budget impact models (BIMs) and analyses that demonstrate cost-effectiveness within the Swiss framework of International Price Comparison and Therapeutic Cross-Comparison.
Strategic engagement planning with key market access stakeholders (FOPH/BAG, payers, clinicians).
Support for price negotiations based on robust value arguments and FOPH's pricing methodologies.
Our Partners' Focus: Regulatory Submissions & Company Establishment
Strategic advice and comprehensive services for regulatory approval with Swissmedic.
Management of the entire lifecycle of your products from initial marketing authorization applications to maintenance (variations, renewals).
Ensuring compliance with all Swissmedic regulations and preparing all necessary documentation modules.
Founding Company Seat: To obtain market access for your medicinal product in Switzerland, your company must have a legal entity (a branch or subsidiary) established in Switzerland. Together with our partners, we assist you in finding an attractive location for your establishment and facilitate all necessary legal and administrative formalities.
